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Elucidating oncogenic pathways in prostate cancer is an arduous task. In this issue of Cancer Cell, 
Yu and colleagues show that repression of Adrenergic Receptor Beta-2 gene expression by Enhancer 
of Zeste 2 results in acquisition of transforming activities. It is interesting that these activities point 
to a role for GTPases as important regulators of transformation in prostate cancer cells. They further 
implicate epithelial-mesenchymal transition as a biologic end point in this process. Overall, on the 
basis of their findings, the authors nominate a novel oncogenic pathway for prostate cancer that 
deserves critical thought and attention.The identification and functional anal-
ysis of oncogenic and tumor suppres-
sor proteins continue to drive progress 
in basic and translational oncologic 
research. Recent studies have shown 
that oncogenic transcription factors 
are complex oncoproteins that func-
tion primarily by recruiting inhibitors 
of gene transcription to target pro-
moters, resulting in transcriptional 
repression of selected genes (Hor-
maeche and Licht, 2007). Enhancer 
of Zeste 2 (EZH2), a member of this 
group of transcriptional repressors, 
has recently gained attention as an 
important and uniquely acting onco-
genic protein (Sparmann and van 
Lohuizen, 2006). EZH2 is a member 
of the polycomb group of proteins, 
which form up to four different mul-
tiprotein Polycomb Repressive Com-
plexes (PRCs). PRCs bind to specific 
target genes and alter their expres-
sion through covalent modification 
of chromatin. These transcriptional 
regulators play important roles in 
normal development (Sparmann and 
van Lohuizen, 2006). As an HMTase 
specific for histone H3 K27, EZH2 is 
a catalytically active member of three 
of these complexes: PRCs 2, 3, and 
4 (Kuzmichev et al., 2005). Specific 
components of these three PRCs 
are expressed at high levels during 
embryonic development, and EZH2, 
specifically, has been shown to pre-
vent stem cell exhaustion and block muscle myoblast differentiation (Hor-
maeche and Licht, 2007). Overexpres-
sion of EZH2 has been associated 
with various malignancies, including 
melanoma and endometrial, prostate, 
breast, and lymphoid cancers (Spar-
mann and van Lohuizen, 2006).
In their article in this issue of Can-
cer Cell, Yu et al. demonstrate that 
the creative use of integrated genom-
ics combined with effective broad-
based laboratory testing can reveal 
important and unanticipated molecu-
lar pathways in malignant progres-
sion (Yu et al., 2007). Previous work 
from their laboratory demonstrated 
that EZH2 is overexpressed in pros-
tate cancer and is associated with 
biochemical recurrence after radi-
cal prostatectomy (Varambally et al., 
2002). In their current report, these 
investigators describe their use of 
gene expression arrays and pub-
lic gene expression data sets from 
human tumors to define an EZH2 
repression signature for prostate 
and breast cancer. Promoter occu-
pancy mapping studies restricted 
the focus to an interesting candidate 
for EZH2 repression in prostate can-
cer cells, Adrenergic Receptor Beta-
2 (ADRB2).
Additional genetic studies showed 
that EZH2 expression suppressed 
ADRB2 transcript and protein levels 
and that, in general, EZH2 levels were 
inversely associated with ADRB2 Cancer Cell 12, expression in prostate cancer cells. 
Extensive molecular analyses and 
chemical inhibitor studies confirmed 
that EZH2 overexpression stimulated 
PRC2 occupancy of the ADRB2 pro-
moter.
The authors extended these obser-
vations through direct testing of the 
biologic importance of EZH2-ADRB2 
targeting. Those studies revealed 
that inhibition of ADRB2 had no 
effect on proliferation yet significantly 
increased the invasiveness and motil-
ity of prostatic epithelial cells in vitro. 
Conversely, overexpression of ADRB2 
or treatment with the agonist isopro-
terenol reversed the invasive pheno-
type in multiple models. An interest-
ing note was that downregulation of 
ADRB2 also led to expression of cell 
biomarkers consistent with an epithe-
lial-mesenchymal transition (EMT), 
i.e., increased vimentin and N-cad-
herin and decreased β-catenin and 
integrin β4 expression. It is notable 
that levels of E-cadherin, a critical 
regulator of EMT, were not signifi-
cantly affected by ADRB2 knock-
down in benign RWPE prostatic 
epithelial cells. Further studies using 
prostate cancer xenograft models 
showed that EZH2 knockdown or 
isoproterenol treatment suppressed 
tumor growth in vivo. Finally, ADRB2 
immunostaining was considerably 
reduced in metastatic prostate can-
cer specimens, and this was inde-November 2007 ©2007 Elsevier Inc. 405
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Previewspendently predictive of 
biochemical recurrence after 
radical prostatectomy.
This article highlights the 
successful use of cell line 
and tumor gene expression 
profiling data together with 
genome-wide location data 
to identify EZH2-repressed 
candidate genes that have 
potential biologic and clinical 
importance. The selection 
and further pursuit of ADRB2 
as an important EZH2 target 
resulted in noteworthy new 
information about the onco-
genic properties of EZH2 in 
prostate cancer.
An important and intrigu-
ing aspect of this study is 
the authors’ observation 
that the oncogenic activities 
of EZH2-stimulated ADRB2 
repression involve induction 
of an EMT. As pointed out 
by the authors, this obser-
vation is consistent with inhibition of 
ADRB2-stimulated, cAMP-mediated 
induction of Rap1 activities. Rap1 is 
a Ras-like small GTPase that is acti-
vated by many extracellular stimuli 
and is involved in cell adhesion (Koo-
istra et al., 2007). Specifically, activa-
tion of Rap1 by cAMP has been shown 
to promote cell-matrix and cell-cell 
adhesion through regulation of β1-3 
integrins and E-cadherin, maintain-
ing the differentiated epithelial phe-
notype. Overall, these data suggest 
the existence of a transformation 
pathway that involves abrogation of 
cAMP-mediated Rap1 maintenance 
of epithelial phenotypic properties 
by EZH2’s repression of ADRB2. This 
would result in an EMT (Figure 1).
An interesting note is that a recent 
study identified another putative 
tumor suppressor protein that is 
repressed by EZH2-DOC-2/DAB2-
interacting protein/ASK-interacting 
protein1 (hDAB2IP/AIP1), which also 
regulates GTPase activities (Chen 
et al., 2005). This GTPase-activat-
ing protein stimulates Hras, Rras, 
and TC21 but not Rap1 GTPase 
activities and suppresses epidermal 
growth factor-stimulated prostate 
cancer cell growth (Wang et al., 2002). 
The effects of EZH2’s repression of 
hDAB2IP/AIP1 on the epithelial phe-
notype have not been reported. Yet it 
has been previously established that 
receptor tyrosine kinase signaling 
through Ras and small GTPases can 
result in EMT (Guarino et al., 2007). 
Under some conditions, Rap1 can 
be affected by upstream tyrosine 
kinase stimulation (Kooistra et al., 
2007). This points to the possibil-
ity that signaling from both tyrosine 
kinase activation and ADRB2 activa-
tion converges on Rap1, providing 
additional regulation of EMT and the 
transformation state. Although it is 
premature to make generalizations, 
the biologic activities related to EMT 
regulated by these two EZH2-tar-
geted, GTPase-mediated signaling 
pathways are provocative.
It has long been appreciated that 
the prostate is a highly innervated 
contractile organ, capable of respond-
ing to various adrenergic stimuli. It is 
also noteworthy that past studies have 
shown that ADRB2’s activities con-
verge with androgenic stimulation to 
contribute to prostatic differentiation in 
vivo (Guthrie et al., 1990). More recent 
genetic observations also point to the 
potential of ADRB2 as a tumor sup-
pressor: specifically, poly-
morphisms in ADRB2 were 
shown to be associated with 
increased risk of breast and 
colorectal cancers (Takezaki 
et al., 2001). However, addi-
tional genetic and biologic 
studies that further address 
the molecular mechanisms 
underlying ADRB2’s tumor 
suppressor activities and 
their subversion by EZH2, 
as revealed by Yu et al., are 
warranted.
The results of Yu et al. 
raise some specific ques-
tions to begin this process. 
Are other molecules in 
GTPase-mediated signal-
ing pathways affected by 
EZH2/PRC2 gene repres-
sion? Are those tumor sup-
pressor pathways and their 
subversion by EZH2 spe-
cific to prostate cancer? 
What are the endogenous 
agonists and/or protein/peptide 
modifiers that regulate ADRB2 sig-
naling in prostate epithelial cells? 
Can these pathways be exploited 
in the development of novel cancer 
therapeutics? These questions and 
others are now open for discussion 
and study.
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figure 1. EZH2-Stimulated Repression of GTPase-Regulated 
Signaling Pathways Involves Induction of EMT
EZH2-stimulated ADRB2 repression involves induction of gene ex-
pression activities and induction of an EMT in prostate cancer cells 
(Yu, et al., 2007). These activities are consistent with downregulation 
of a signaling pathway involving ADRB2-stimulated, cAMP-mediated 
Rap1 activation. Stimulation of Rap1 by cAMP has been shown to 
maintain the differentiated epithelial phenotype through regulation of 
cell adhesion, and thus suppression of this signaling pathway is con-
sistent with EMT. Recent studies also show that EZH2 downregulates 
hDAB2IP/AIP1, a GTPase-activating protein and putative tumor sup-
pressor that inhibits EGF-Ras signaling in prostate cancer cells. Thus, 
EZH2 activities may sustain RTK-stimulated EMT. Overall, EZH2 may 
induce EMT and malignant activities through subversion of multiple 
pathways that involve GTPases.406 Cancer Cell 12, November 2007 ©2007 Elsevier Inc.
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Barrette, T.R., Kumar-Sinha, C., Sanda, M.G., 
Ghosh, D., Pienta, K.J., Sewalt, R.G., Otte, 
A.P., et al. (2002). Nature 419, 624–629.A growing body of evidence has 
revealed that chromatin changes 
correlate with differences in gene 
expression, leading to the widely held 
view that transcription factor binding 
at promoters acts through nucleo-
somes to activate or repress gene 
expression (Li et al., 2007). However, 
it is unclear how the various chroma-
tin differences can lead to changes in 
the on-versus-off state of promoters. 
One idea is that histone modifications 
alter the accessibility of DNA by sta-
bilizing interactions between chroma-
tin-associated proteins and the his-
tones that they bind to (Cosgrove et 
al., 2004). But then how do these his-
tone tail interactions result in up- or 
downregulation of gene expression? 
A paradigm originating from studies 
of the yeast PHO5 promoter is that 
nucleosomes are simply evicted from 
promoters, and the naked DNA that 
results allows for transcription fac-
tors to gain access to their binding 
sites and for the basal transcriptional 
machinery to assemble (Boeger et 
al., 2003; Reinke and Horz, 2003). 
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Indeed, a distinguishing feature of 
active promoters in general is that 
they are depleted in nucleosomes 
relative to silent promoters (Mito et 
al., 2005).
A limitation of studies that have 
been used to map chromatin char-
acteristics, such as histone modi-
fications and variants, is that they 
provide data that are averaged from 
large numbers of individual DNA mol-
ecules. For example, ChIP-chip and 
real-time PCR assays can provide 
sensitive measurements of chromatin 
features and of nucleosome occu-
pancy, but these are relative mea-
surements that cannot distinguish 
between a change in the amount of 
a feature relative to a control and its 
absolute abundance (van Leeuwen 
and van Steensel, 2005). Therefore, 
it has remained possible that the 
reduction in nucleosome occupancy 
seen in such studies is not com-
plete eviction of nucleosomes, but 
rather partial loss or even transient 
unwrapping. To address this uncer-
tainty, Peter Jones’ group introduced 
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a single-molecule modification of the 
DNA methylation mapping technique 
for mapping chromatin accessibil-
ity (Fatemi et al., 2005; Kladde et al., 
1996) (Figure 1A). The M.SssI DNA 
methyltransferase specifically meth-
ylates the cytosines of CG dinucleo-
tide base pairs, making these bases 
resistant to deamination by treatment 
with sodium bisulfite. As a result, 
M.SssI methylation of nuclei followed 
by DNA extraction and bisulfite treat-
ment results in DNA with CGs intact, 
but with all other cytosines converted 
to uracil. The uracil bases are repli-
cated as if they were thymines, so 
that PCR amplification, cloning, and 
sequencing of a region using M.SssI- 
and bisulfite-treated DNA yields 
sequences from single molecules in 
which CGs that have been methyl-
ated by M.SssI are sequenced as 
CGs, but those that have escaped 
M.SssI methylation are sequenced 
as TGs. In this way, blocking of a CG 
from the action of M.SssI in nuclei 
can be quantified by sequencing a 
collection of PCR-generated clones, 
s: 
8109, USA
on of gene expression, including 
riants, and DNA methylation. In 
e-molecule approach to explore 
sion in cancer cells. They show 
rt sites of the MLH1 CpG island. 
tly lost as transcription becomes 
require that promoters are main-
